---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-015592"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2026-01-20T23:59:59+00:00"
generated_at: "2026-05-16T09:33:04.866986+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# DBV Technologies secures €166.7M from full exercise of warrants after positive VITESSE trial

## Summary
- €166.7M gross proceeds from full exercise of ABSA Warrants (34.1M) and BS Warrants (71.0M) issued March 2025.
- Proceeds to fund BLA submission and U.S. launch preparations for VIASKIN Peanut patch in children 4-7 years if approved.
- Company expects to be funded for at least 12 months, including through potential commercial launch.
- Exercise triggered by positive VITESSE Phase 3 topline results announced December 16, 2025; no warrants remain outstanding.
- 59.7M new ordinary shares issued; additional pre-funded warrants may access up to 154M new shares in future.

## SEC filing metadata
- accession: 0001193125-26-015592
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2026-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312526015592/0001193125-26-015592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312526015592/d74681d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-015592
- JSON: https://secwatch.observer/filing/0001193125-26-015592.json
- Plain text: https://secwatch.observer/filing/0001193125-26-015592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.